Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia

Pediatric Blood and Cancer

Volumn 60, Issue 7, 2013, Pages 1161-1164

  Buaboonnam, Jassada ^a,b   Cao, Xueyuan ^a   Pauley, Jennifer L ^a   Pui, Ching Hon ^a,c   Ribeiro, Raul C ^a,c   Rubnitz, Jeffrey E ^a,c   Inaba, Hiroto ^a,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; Asparaginase; Children; Methotrexate; Relapse

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ASPARAGINASE; ASPARAGINASE MACROGOL; CYTARABINE; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; OCTREOTIDE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BLOOD CELL COUNT; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; INFANT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MONOCYTIC LEUKEMIA; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PANCREATITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; SALVAGE THERAPY; SCHOOL CHILD; SEPSIS; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; METHOTREXATE; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 84878260418     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24470     Document Type: Article

References (27)

1. Georgina WH. Childhood myeloid leukaemias. Best Pract Res Clin Haematol 2001; 14: 573-591.
2. Aladjidi N, Auvrignon A, Leblanc T, et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol 2003; 21: 4377-4385.
3. Martin MG, Augustin KM, Uy GL, et al. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF. Am J Hematol 2009; 84: 733-737.
4. Sarper N, Yalman N. FLAG (fludarabine, high-dose cytarabine and G-CSF) for refractory and high-risk relapsed acute leukemia in children. Med Pediatr Oncol 2000; 34: 163.
5. Sander A, Zimmermann M, Dworzak M, et al. Consequent and intensified relapse therapy improved survival in pediatric AML: Results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia 2010; 24: 1422-1428.
6. Rubnitz JE, Razzouk BI, Lensing S, et al. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer 2007; 109: 157-163.
7. Temming P, Qureshi A, Hardt J, et al. Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: Retrospective cohort study in a single centre in the United Kingdom. Pediatr Blood Cancer 2011; 56: 625-630.
8. Styczynski J, Wysocki M, Debski R, et al. Ex vivo drug resistance profile in childhood acute myelogenous leukemia: No drug is more effective in comparison to acute lymphoblastic leukemia. Leukemia Lymphoma 2002; 43: 1843-1848.
9. Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: A pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010; 28: 955-959.
10. Yap BS, Mccredie KB, Keating MJ, et al. Asparaginase and methotrexate combination chemotherapy in relapsed acute lymphoblastic-leukemia in adults. Cancer Treat Rep 1981; 65: 83-87.
11. Hudson MM, Dahl GV, Kalwinsky DK, et al. Methotrexate plus L-asparaginase. An active combination for children with acute nonlymphocytic leukemia. Cancer 1990; 65: 2615-2618.
12. Chłopkiewicz B, Koziorowska J. Role of amino acid depletion in combined treatment of neoplastic cells with methotrexate and L-asparaginase. Cancer Res 1975; 35: 1524-1529.
13. Rots MG, Pieters R, Jansen G, et al. A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia. Eur J Cancer 2001; 37: 492-498.
14. Okada S, Hongo T, Yamada S, et al. In vitro efficacy of L-asparaginase in childhood acute myeloid leukaemia. Br J Haematol 2003; 123: 802-809.
15. Kurt B, Flynn P, Shenep JL, et al. Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer 2008; 113: 376-382.
16. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649.
17. Capizzi RL. Asparaginase-methotrexate in combination chemotherapy: Schedule-dependent differential effects on normal versus neoplastic cells. Cancer Treat Rep 1981; 65: 115-121.
18. Vadlamudi S, Krishna B, Reddy VVS, et al. Schedule-dependent therapeutic synergism for L-asparaginase and methotrexate in leukemic (L5178Y) mice. Cancer Res 1973; 33: 2014-2019.
19. Capizzi RL, Summers WP, Bertino JR. L-asparaginase induced alteration of amethopterin (methotrexate) activity in mouse leukemia L5178Y. Ann NY Acad Sci 1971; 186: 302-311.
20. Mandelli F, Amadori S, Pacilli L, et al. Preliminary results of the combination methotrexate-asparaginase in patients with acute non-lymphoid leukemia. Biomedicine 1978; 29: 116-117.
21. van den Berg H. Asparaginase revisited. Leuk Lymphoma 2011; 52: 168-178.
22. Silverman LB, Supko JG, Stevenson KE, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood 2010; 115: 1351-1353.
23. Kamen BA. L-asparaginase and methotrexate combinations: Clashes of empiric success and laboratory models? J Pediatr Hematol/Oncol 2007; 29: 587-588 510.1097/MPH.1090b1013e3181483e3181481b.
24. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109: 896-904.
25. Dubbers A, Wurthwein G, Muller HJ, et al. Asparagine synthetase activity in paediatric acute leukaemias: AML-M5 subtype shows lowest activity. Br J Haematol 2000; 109: 427-429.
26. Goker E, Kheradpour A, Waltham M, et al. Acute monocytic leukemia: A myeloid leukemia subset that may be sensitive to methotrexate. Leukemia 1995; 9: 274-276.
27. Tokimasa S, Yamato K. Does octreotide prevent L-asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia? Br J Haematol 2012; 157: 381-382.